Compare AbCellera Biologics Inc (ABCL) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? AbCellera Biologics Inc trades at $9.05 (market cap $2.99B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VUSB | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.76 | $50.03 |
52-Week Low | $2.78 | $49.60 |
Enterprise Value | $2.58B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
